Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
CA 2412845 C · Owner: Lan, Yan · Inventors: Lan, Yan; Holden, Sylvia A.; Gillies, Stephen D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compositions for treating tumors and the use of such compositions. Disclosed compositions enhance the uptake of immunocytokines into , tumors, and are based on a combination of an immunocytokine with an immunocytokine , uptake enhancing agent. The immune uptake enhancing agent is taxol docetaxel, 10-deacetyl, Baccatin III, cyclophosphamid or carboplatin and can be administered to a , mammal prior to the immunokine. Disclosed compositions are particularly useful for , reducing tumor size and metastasis in a mammal.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 29, 2001 and granted July 22, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 29, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 29, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.